Risk of COVID-19 for patients with cancer

Yang, Xia; Jin, Rui; Zhao, Jing; Li, Wen; Shen, Huahao

doi:10.1016/s1470-2045(20)30150-9

Cited by 386 publications

(408 citation statements)

References 3 publications

Supporting

Mentioning

371

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, as subsequently highlighted by other authors, the true incidence of COVID-19 in patients with cancer would be more informative in assessing whether such patients have an increased risk (and morbidity) from this viral illness [6]. Furthermore, the limited cancer patient population described in this first report from the literature, was curiously characterized by the lack of individuals receiving anticancer immunotherapy.…”

Section: Corona Virus Disease-19 Pandemic and Cancer Patientsmentioning

confidence: 69%

“…There is a possibility that such patients would be also more prone to fall in the cytokine storm in the case of SARS-CoV-2 infection. Nevertheless, these patients do not correspond to the average advanced cancer patient, who is supposed to be immunosuppressed, with a blunted immune status [6]. The epidemiology of the COVID-19 observed up today suggests that SARS-CoV-2 tends to infect more frequently the frail patient populations, such as the elderly and cancer patients [4,5].…”

Section: Therapeutic Implications: Tocilizumab and The Risk Of Hasty Comentioning

confidence: 99%

“…The epidemiology of the COVID-19 observed up today suggests that SARS-CoV-2 tends to infect more frequently the frail patient populations, such as the elderly and cancer patients [4,5]. Cancer is usually associated with overexpression of immunosuppressive cytokines, suppression of proinflammatory danger signals, impaired dendritic cell maturation, and enhanced immunosuppressive leukocyte populations [6]. Since ICI can restore the immune-competence, if on one hand it can be paradoxically needed to develop the cytokine storm characterizing the acute respiratory distress syndrome (ARDS) phase, on the other hand the epidemiological features of SARS-CoV-2 infection lay for a lower probability to affect these patients compared with their chemo-treated immune-suppressed counterpart.…”

Section: Therapeutic Implications: Tocilizumab and The Risk Of Hasty Comentioning

confidence: 99%

See 2 more Smart Citations

Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors

2020

View full text Add to dashboard Cite

Section: Corona Virus Disease-19 Pandemic and Cancer Patientsmentioning

confidence: 69%

Section: Therapeutic Implications: Tocilizumab and The Risk Of Hasty Comentioning

confidence: 99%

Section: Therapeutic Implications: Tocilizumab and The Risk Of Hasty Comentioning

confidence: 99%

See 1 more Smart Citation

Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors

2020

View full text Add to dashboard Cite

“…In 2015, dasatinib was replaced due to treatment failure. In March 2019, the efficacy evaluation was failure: the BCR-ABL fusion gene quantification was 25.47%, the chromosome was 46, XY, t (9;22) (q34;q11)[10] /47, XY, +8[10] and there was a T315I mutation.He participated in an ongoing clinical trial of an alternative CML treatment (HQP1351) in May 2019 and achieved complete cytogenetic remission (CCyR) in July 2019. The chromosome was 47, XY, +8[20], and the fusion gene quantification was 0.49%.…”

mentioning

confidence: 99%

The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey

Wang

Guo

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Since late December 2019, the outbreak of the novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic in China and more than 100 countries and regions in the world. So far, there is rare data on the prevalence of COVID-19 in patients with chronic myelogenous leukemia (CML). We aimed to describe the clinical course, outcomes of CML patients with COVID-19 and prevalence of COVID-19 in CML patients. Methods In this multi-center survey, cross-sectional survey, observational study, the clinical data of CML patients with COVID-19 in each center were collected. Simultaneously, an online survey was conducted for information about the CML patients under the management at each center by asking the CML patients to complete a questionnaire,from February 15, 2020 to February 21, 2020. The questionnaire includes demographic data, place of residence, smoking status, CML diagnosis and treatment, comorbidities, combined medications, epidemiological history, symptoms(fever, cough, shortness of breath, etc) during the epidemic. Additional clinical data was collected on respondents suspected or confirmed to have COVID-19. We described and analyzed the prevalence of COVID-19 in CML patients, and focus on the clinical characteristics and outcomes of COVID-19 patients. Data were compared between the CML patients with optimal response and those with non-optimal response. The primary outcome was prevalence of COVID-19 in CML patients, as of Feb 21, 2020. Secondary outcomes included the history of epidemiology of CML patients, the clinical characteristics and outcomes of CML patients with COVID-19 . Findings Of 392 respondents, 223( 56.9%) were males, and 240( 61.2%) were 50 years or younger. Only 10 patients took drugs irregularly due to the influence of the epidemic because of traffic control, pharmacies unable to operate normally, etc. In the history of epidemiology, there were 4 patients with definite contact with COVID-19, of which 3 were remote contact and 1 was close contact. 12 respondents had fever, cough or shortness of breath during the epidemic, 1 case (common type) was confirmed with COVID-19 and cured after treatment. 1 patient was clinically diagnosed and succumbed. 1 of 299 (0.3%) patients with an optimal response was diagnosed with COVID-19. Of the 50 patients who failed to respond to CML treatment or had a poor response, 1 patient (2%) had a clinical diagnosis of COVID-19. Interpretation While the 392 CML respondents required regular referrals to hospitals, they did not have much contact with COVID-19 patients during the outbreak. Patients who failed to achieved an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2. Older patients with comorbidities are at increased risk of death. Dan-Yu Wang, Jing-Ming Guo, Zhuang-Zhi Yang Co first author Dan-Yu Wang,Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen Guangdong, China,E-mail: 15818662864@139.com Jing-Ming Guo, Department of Hematology,Yi Chang Central People's Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang Hubei, China,E-mail:gjm425@163.com Zhuang-Zhi Yang, Department of Hematology,Suizhou Central Hospital, Suizhou Hubei, China,E-mail:yzhzh88@163.com Correspondence author: Guo-Lin Yuan, MD, Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Hubei, China. E-mail: yuanguo1973@163.com Li Meng, MD, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan Hubei, China. E-mail: mengli@tjh.tjmu.edu.cn Wei-Ming Li, MD, Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of science and Technology, Wuhan Hubei, China. E-mail: lee937@126.com

show abstract

“…Authors: Sara Cherri (1), Silvia Noventa (1), Alberto Zaniboni(1) with the hypothesis that cancer could lead to a higher risk of both infection and death from covid19. However, other authors [3] have highlighted the limitations of these studies. In fact, if we can consider at risk of worse outcome an oncological patient with advanced age and comorbidity such as obesity, hypertension and diabetes, on the other hand we cannot certainly conclude that cancer itself is to be considered a negative prognostic factor of complication and / or exitus in case of covid19 infection.…”

Section: Is the Oncologic Patient More Susceptible To Covid19 But Permentioning

confidence: 99%

Is the oncologic patient more susceptible to covid19 but perhaps less likely to undergo severe infection-related complications due to fewer cytokines storm as a consequent of the associated immunodeficiency?

2020

View full text Add to dashboard Cite

Risk of COVID-19 for patients with cancer

Cited by 386 publications

References 3 publications

Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors

Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors

The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey

Is the oncologic patient more susceptible to covid19 but perhaps less likely to undergo severe infection-related complications due to fewer cytokines storm as a consequent of the associated immunodeficiency?

Contact Info

Product

Resources

About